Gene · 100885779
LINC-ROR: long independently transcribed non-coding RNA, regulator of reprogramming
12 sourcesgene-search-2026-11-11-0.2.0
Download JSON
Cite this record
ConductScience Library. LINC-ROR: long independently transcribed non-coding RNA, regulator of reprogramming. Genes, record 100885779. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/100885779
On this page
Gene
Proteins0
Reviewed human proteins whose Swiss-Prot entry states the gene.
None in this release.
Patents0
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
None in this release.
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,447
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | LINC-ROR papers | Newest fiscal year |
|---|---|---|---|
| P50CA058223 | SPORE in Breast Cancer | 19 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 11 | 2025 |
| P30ES010126 | UNC Center for Environmental Health and Susceptibility | 11 | 2025 |
| ZIAES101586 | Nuclear receptors: action, functions, and roles in disease | 11 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 8 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 8 | 2025 |
| I01BX004293 | CYP11A1-derived secosteroids as therapeutic agents in UVB induced skin cancer | 5 | 2025 |
| R01AR073004 | Mechanism of action and function of novel secosteroid 20(OH)D3 in the skin | 5 | 2025 |
| U01HG006379 | EHR-based Genomic Discovery and Implementation [Funded Extension] | 5 | 2025 |
| U01HG008685 | eMERGE Phase IV Clinical Center at Mass General Brigham | 5 | 2025 |
1 to 10 of 1,447Source NIH's project files
See all 1,447 nih grantsPapers3,017
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mechanism-based reporting patterns of infection-related adverse events with systemic psoriasis therapies in FAERS. | J Dermatolog Treat | 2026 | 42806931 | PubTator, text mining | PubMed |
| Early-onset respiratory adverse event patterns of omalizumab in pediatric patients: an age-stratified FAERS pharmacovigilance study. | Acta Clin Belg | 2026 | 42647060 | PubTator, text mining | PubMed |
| Safety Comparison of Acetylcholinesterase Inhibitors Using FAERS Spontaneous-Reporting Data: Drug-Specific Reporting Signals and Time-to-Onset Dynamics. | Curr Alzheimer Res | 2026 | 42634550 | PubTator, text mining | PubMed |
| Real-world safety profile of trazodone: Evidence from FAERS pharmacovigilance data (2004-2024). | Australas Psychiatry | 2026 | 42629597 | PubTator, text mining | PubMed |
| Integrated pharmacovigilance assessment of drug-associated cholangitis: signal detection, clinical characterization, and mechanistic insights. | Front Pharmacol | 2026 | 42597371 | PubTator, text mining | PubMed |
| Circadian Regulation of Glucose Metabolism: Implications for Pathogenesis and Chronotherapy of Type 2 Diabetes. | Diabetology (Basel) | 2026 | 42583078 | PubTator, text mining | PubMed |
| Circadian rhythms in the tumor microenvironment: spatiotemporal immune regulation and chronotherapeutic opportunities. | Front Immunol | 2026 | 42553207 | PubTator, text mining | PubMed |
| Can Disruption of Circadian Rhythms Be Linked to Radiation-Induced Acute Myeloid Leukaemia? | Cancers (Basel) | 2026 | 42512320 | PubTator, text mining | PubMed |
| Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and reporting-interval characteristics. | Front Pharmacol | 2026 | 42494530 | PubTator, text mining | PubMed |
Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation. | Diabetes Obes Metab | 2026 | 42481928 | PubTator, text mining | PubMed |
1 to 10 of 3,017
See all 3,017 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/100885779
GET https://conductscience.org/api/genes/v1/100885779/grants?page=2